The natural history of multiple sclerosis

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

The natural history of MS is highly variable. There is substantial heterogeneity in the clinical manifestations but, at this point, it is reasonable to consider all idiopathic inflammatory demyelinating diseases of the central nervous system as representing a spectrum of the same disease. In large populations, 20% to 40% have 'benign disease,' defined as having less than moderate disability after 10 years. Benign is a potentially misleading term because many of these patients subsequently will become disabled. Half will develop progressive MS within 10 years and will require some form of walking aid within 15 years following the onset of MS. Survival is not greatly shortened in mildly disabled patients, but the observed mortality is increased four-fold over the general population in patients with advanced disability. Patients with the greatest risk of disability are those with PP MS and RR patients who are older at onset, have pyramidal or cerebellar involvement at onset, and who have frequent or prolonged attacks with incomplete recovery. The biological basis for the variation in the course of MS is understood only in a very limited way. The short- and long-term course of MS may be determined by different biological variables. Short-term benefit in clinical trials should not be assumed to indicate long-term reduction in the risk of permanent disability.

Original languageEnglish (US)
Pages (from-to)119-146
Number of pages28
JournalNeurologic Clinics
Volume13
Issue number1
StatePublished - 1995

Fingerprint

Multiple Sclerosis
Demyelinating Diseases
Risk Reduction Behavior
Natural History
Population
Walking
Central Nervous System
Clinical Trials
Survival
Mortality

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The natural history of multiple sclerosis. / Weinshenker, Brian G.

In: Neurologic Clinics, Vol. 13, No. 1, 1995, p. 119-146.

Research output: Contribution to journalArticle

@article{ebfda99f7681494ea3d0a4a6b34e3f9f,
title = "The natural history of multiple sclerosis",
abstract = "The natural history of MS is highly variable. There is substantial heterogeneity in the clinical manifestations but, at this point, it is reasonable to consider all idiopathic inflammatory demyelinating diseases of the central nervous system as representing a spectrum of the same disease. In large populations, 20{\%} to 40{\%} have 'benign disease,' defined as having less than moderate disability after 10 years. Benign is a potentially misleading term because many of these patients subsequently will become disabled. Half will develop progressive MS within 10 years and will require some form of walking aid within 15 years following the onset of MS. Survival is not greatly shortened in mildly disabled patients, but the observed mortality is increased four-fold over the general population in patients with advanced disability. Patients with the greatest risk of disability are those with PP MS and RR patients who are older at onset, have pyramidal or cerebellar involvement at onset, and who have frequent or prolonged attacks with incomplete recovery. The biological basis for the variation in the course of MS is understood only in a very limited way. The short- and long-term course of MS may be determined by different biological variables. Short-term benefit in clinical trials should not be assumed to indicate long-term reduction in the risk of permanent disability.",
author = "Weinshenker, {Brian G}",
year = "1995",
language = "English (US)",
volume = "13",
pages = "119--146",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - The natural history of multiple sclerosis

AU - Weinshenker, Brian G

PY - 1995

Y1 - 1995

N2 - The natural history of MS is highly variable. There is substantial heterogeneity in the clinical manifestations but, at this point, it is reasonable to consider all idiopathic inflammatory demyelinating diseases of the central nervous system as representing a spectrum of the same disease. In large populations, 20% to 40% have 'benign disease,' defined as having less than moderate disability after 10 years. Benign is a potentially misleading term because many of these patients subsequently will become disabled. Half will develop progressive MS within 10 years and will require some form of walking aid within 15 years following the onset of MS. Survival is not greatly shortened in mildly disabled patients, but the observed mortality is increased four-fold over the general population in patients with advanced disability. Patients with the greatest risk of disability are those with PP MS and RR patients who are older at onset, have pyramidal or cerebellar involvement at onset, and who have frequent or prolonged attacks with incomplete recovery. The biological basis for the variation in the course of MS is understood only in a very limited way. The short- and long-term course of MS may be determined by different biological variables. Short-term benefit in clinical trials should not be assumed to indicate long-term reduction in the risk of permanent disability.

AB - The natural history of MS is highly variable. There is substantial heterogeneity in the clinical manifestations but, at this point, it is reasonable to consider all idiopathic inflammatory demyelinating diseases of the central nervous system as representing a spectrum of the same disease. In large populations, 20% to 40% have 'benign disease,' defined as having less than moderate disability after 10 years. Benign is a potentially misleading term because many of these patients subsequently will become disabled. Half will develop progressive MS within 10 years and will require some form of walking aid within 15 years following the onset of MS. Survival is not greatly shortened in mildly disabled patients, but the observed mortality is increased four-fold over the general population in patients with advanced disability. Patients with the greatest risk of disability are those with PP MS and RR patients who are older at onset, have pyramidal or cerebellar involvement at onset, and who have frequent or prolonged attacks with incomplete recovery. The biological basis for the variation in the course of MS is understood only in a very limited way. The short- and long-term course of MS may be determined by different biological variables. Short-term benefit in clinical trials should not be assumed to indicate long-term reduction in the risk of permanent disability.

UR - http://www.scopus.com/inward/record.url?scp=0028928973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028928973&partnerID=8YFLogxK

M3 - Article

C2 - 7739500

AN - SCOPUS:0028928973

VL - 13

SP - 119

EP - 146

JO - Neurologic Clinics

JF - Neurologic Clinics

SN - 0733-8619

IS - 1

ER -